Resonance Health Ltd · ASX:RHT
Resonance Health — Shareholder Meeting (November 2024)
15 slides from Resonance Health's shareholder meeting presentation, Nov 28, 2024
Slide 1: AGM Presentation
For personal use only Resonance Health Andrew Harrison, CEO Benjamin Carruthers, CFO AGM Presentation 28th November 2024 1 1
Slide 2: The Resonance Business
The Resonance Business For personal use only • Resonance Health is an ASX listed provider of Software-as-a Medical Device (SaMD), and Clinical Trial Services to Hospitals, Radiology Centres, and Pharma globally • SaMD services are used in more than 400 locations globally • Actively involved in over
Slide 3: Resonance Health business segments
Resonance Health specialises in providing central imaging analysis (SaMD) services, contract research organisation (CRO – Resonance Clinical) services and investigator site (TrialsWest) services to global pharmaceutical and For personal use only biotechnology companies, hospitals and radiology centr
Slide 4: Clinical Trial Ecosystem
Clinical Trial Ecosystem For personal use only Clinical Trials are central to the development of new medicines and vaccines to prevent and treat disease. They require the coordinated action of numerous key stakeholders. Service Providers Pharma & Biotech Companies Certain activities may be outsource
Slide 5: FY24 Results Summary
For personal use only FY24 Results Summary Revenue Normalised Operating EBITDA1 Normalised Operating $8.6M $1.12M EBITDA margin1 Up 95% pcp 13% Up 234% pcp Free Cashflow2 Free Cashflow / EPS $1.0M Operating EBITDA 0.04 CPS Up 314% pcp 90% Up 0.21 CPS pcp Net Cash $3.68M 1 Normalised Operating EBITDA
Slide 6: FY24 Highlights
For personal use only FY24 Highlights ü Revenue of $8.6M, an increase of $4.2M or 95% on the prior corresponding period (PCP) Revenue ü Reported Normalised EBITDA of $0.69M, an increase of $1.5M or 183% on PCP $10,000,000 ü 1Normalised Operating EBITDA of $1.12M, an increase of $1.96M or 234% on the
Slide 7: 1st Quarter FY25 Performance
For personal use only 1st Quarter FY25 Performance ü Receipts from customers for the first quarter of $3.2M - up 186% or $2.07M from pcp FY23 of $1.12M, ü Record cash receipts from customers over 12 months to 30 Sep 2024 of $10.2M up 133% or $5.8M from pcp to 30 Sep 2023 ü Uneven timing of revenue a
Slide 8: Central Imaging Analysis (SaMD) Business
For personal use only Central Imaging Analysis (SaMD) Business ü Analysis volumes and revenue increased in the SaMD business as compared to the prior year ü Entered into several new clinical trial service agreements to offer SaMD products into clinical trials as well as extending certain existing cl
Slide 9: Resonance Clinical (CRO) Business
For personal use only Resonance Clinical (CRO) Business ü Recent $13.78M contract illustrates success of CRO business strategy ü $20.1M in total contract wins since August 2023 ü Developed highly sophisticated CRO team capability ü Highly complementary business using both SaMD (FerriScan, HepaFat) a
Slide 10: Investigator Sites
For personal use only Investigator Sites FY24 Revenue Proforma TrialsWest FY ü Deal was struck to acquire TrialsWest in 3rd Quarter FY24 at that time, Contribution full year Revenue & EBITDA was forecast to be $2M & $0.667K respectively at a 33% operating margin 19% ü Project wins and new trial comm
Slide 11: Strong Path to Growth
For personal use only Strong Path to Growth There are several key near term drivers of growth Automation Increase capacity of the business through automation including use of advanced AI products Early commercialisation of a non-invasive MRI Liver Fibrosis device Completion of Extended Proof of Conc
Slide 12: Strong Tailwinds
For personal use only Strong Tailwinds Australian Clinical Trial Market Global Clinical Trial Market Key Drivers - Australia Key Drivers - Globally ü Approvals and regulatory system ü Increasing rapidity of technological breakthroughs ü Public private health system ü Shortening development timeframe
Slide 13: Business Outlook
For personal use only Business Outlook Strong FY25 Performance is expected on the back of strong FY24 results ü Continued growth in SaMD business volumes ü Current CRO clinical trial will continue to generate revenue in FY25 (expected to be completed during the year) ü New CRO contract win of $13.78
Slide 14: Disclaimer
For personal use only Disclaimer This presentation has been prepared by Resonance Health Ltd (“Resonance Health” or “Company”) and may contain forward-looking statements that are based on current expectations and beliefs and are subject to numerous factors and uncertainties that could cause actual r
Slide 15: Contact Us
For personal use only Contact Us info@resonancehealth.com +61 8 9286 5300 resonancehealth.com resonance-health-ltd/
Resonance Health — Shareholder Meeting (November 2024) on 6ix